Skip to main content
The words approved in red capitalized letters

Aurobindo’s Eugia Pharma Specialities subsidiary gets FDA OK for generic Vidaza

Generic Vidaza is indicated for the treatment of adult patients with several FAB myelodysplastic syndrome subtypes.
Levy

Aurobindo’s Eugia Pharma Specialities subsidiary has received the Food and Drug Administration’s permission for azacitidine for injection, 100 mg single-dose vial, which is the generic of Bristol-Myers Squibb’s Vidaza.

Generic Vidaza is expected to be launched by this month. It is indicated for the treatment of adult patients with the following FAB myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions); refractory anemia with excess blasts; refractory anemia with excess blasts in transformation; and chronic myelomonocytic leukemia.

[Read more: Aurobindo Pharma continues injectable business restructuring]

The medication had an estimated market size of roughly $46 million for the 12 months ending November 2022, according to IQVIA.

X
This ad will auto-close in 10 seconds